OXFORD
BIOMEDICA
Oxford Biomedica Appoints Non-Executive Director
Oxford,
UK - 13 February 2001: Oxford BioMedica ("BioMedica")
announced today that Mr Raj Uppal has been appointed as a
Non-Executive Director to the Board.
Mr Uppal
is a Chartered Accountant and was Finance and Commercial Director
of Quadrant Healthcare plc until the acquisition of Quadrant
by Elan Corporation plc in December 2000. He joined Quadrant
as Finance Director in May 1996. He has been retained by Elan
Pharmaceutical Technologies (the drug delivery division of
Elan) as Senior Vice President. Previously he has worked at
Ferry Pickering Group plc as Deputy Chief Executive.
Commenting
on the announcement, Professor Alan Kingsman, Chief Executive
of Oxford BioMedica, said:
"We are delighted that Raj has joined the team at
BioMedica. His experience in a wide range of industries and
business aspects, and particularly with Quadrant Healthcare,
should be very valuable to BioMedica as it expands its operations
and establishes itself further as a leading company in the
sector. With Raj coming on board, BioMedica now has a Board
of nine people with considerable expertise to manage the Company."
|
Return to the News
| Notes
to Editors
| 1. |
Oxford
BioMedica plc
Established in 1995, the Company specialises in the
development and application of gene-based therapeutics
and immunotherapeutics for the treatment of disease
in the areas of Oncology, Neurobiology and Viral Infection
and in Gene Discovery. Oxford BioMedica plc was floated
on the Alternative Investment Market of the London Stock
Exchange in December 1996.
Currently
Oxford BioMedica has corporate collaborations with Aventis,
AstraZeneca, IDM, Modex Therapeutics, Nycomed Amersham,
Valentis, Virbac and Wyeth. BioMedica has two products
in Phase I/II clinical trials. MetXia®
is in clinical trials for late-stage breast cancer (BC1)
and ovarian cancer (OC1) and TroVax™ is in clinical
trials for late-stage colorectal cancer.
|
|
| For
further information please contact: |
|
|
Oxford BioMedica plc
Professor Alan
Kingsman, Chief Executive |
Tel:
+44 (0)1865 783 000 |
Kings
College, London
Melanie Gardner |
Tel:
+44 (0)207 848 3073 |
| City/Financial
Enquiries
David
Simonson, Melanie Toyne Sewell
Merlin Financial Communications |
Tel:
+44 (0)20 7606 1244 |
| Scientific/Trade
Enquiries
Chris
Gardner, HCC•De Facto Group |
Tel:
+44 (0)20 7496 3300 |
|
Top
of page
Website by College Hill - Life Sciences |
| |
|
|
